Sumatriptan/Naratriptan/Treximet Pregnancy Registry

Please note that the Sumatriptan/Naratriptan/Treximet pregnancy registry was closed on 19 September 2012 and the final study report was issued April 2013.

Information collected at the time of registration included timing, dose and duration of the drug exposure, estimated date of delivery, and sufficient contact information to allow for follow-up of the subsequent pregnancy outcome.

Measures are in place to protect patient confidentiality. The registry advocates the use of an identifier (not patient names) assigned by the registry for the purpose of obtaining follow-up information. Around the patient's estimated date of delivery a short follow-up form was sent to the registering healthcare provider to report on the pregnancy course and outcome.

Final Study Report (April 2013) (PDF format)